Confronting the barriers to develop novel vaccines against brucellosis.
about
Advancement of knowledge of Brucella over the past 50 years.Tripping on acid: trans-kingdom perspectives on biological acids in immunity and pathogenesis.Identification and effect decomposition of risk factors for Brucella contamination of raw whole milk in chinaIn Situ Characterization of Splenic Brucella melitensis Reservoir Cells during the Chronic Phase of Infection in Susceptible MiceCD8+ T cell exhaustion, suppressed gamma interferon production, and delayed memory response induced by chronic Brucella melitensis infection.Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice.A history of the development of Brucella vaccines.Trypanosoma Infection Favors Brucella Elimination via IL-12/IFNγ-Dependent Pathways.Mutant Brucella abortus membrane fusogenic protein induces protection against challenge infection in mice.Novel Solutions for Vaccines and Diagnostics To Combat Brucellosis.Immunogenicity Analysis of a Novel Subunit Vaccine Candidate Molecule-Recombinant L7/L12 Ribosomal Protein of Brucella suis.Identification of Immune Effectors Essential to the Control of Primary and Secondary Intranasal Infection with Brucella melitensis in Mice.Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections.Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice.Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.Allergic Asthma Favors Growth in the Lungs of Infected Mice
P2860
Q30834268-88FC444B-B215-488E-811E-295BA0D34D2FQ34845436-AA564F8A-A1D2-4AF5-916D-0C2738D20E52Q34847504-97153C5E-0626-4AB3-8894-F2058D611FBBQ35777394-B18C1CE0-8EF9-4F7C-98F7-63EA7E4D75C8Q36281282-D346B3A9-0C9D-4F68-A563-C864C4BBC205Q36396770-E1C51B1F-B674-44CF-B082-49EA0C2B3A51Q36938722-CC88EE46-1440-48C4-9670-BC17D8007A00Q38616690-BE91239A-C5BF-4737-B4EF-FBB96964A8E2Q39044190-32DA9915-28CA-431A-88B3-034846C614A2Q40261059-60FD416B-78FF-432A-ACCE-97A9CB773CD6Q40716095-C9DB7E29-598D-44C5-9AFA-BCDC150BE1E4Q40731935-FAEDDD2D-87CE-43E0-B09E-A3EAC31F0BAAQ40978948-F75C65DE-351E-4690-833B-E6E41505B268Q41691222-E2A2E3AF-DE99-4CE4-BD63-2A7E6FBB19EAQ47129535-B811EAA7-F739-44A3-BF98-232478E16A46Q58789999-DC3BA479-5862-46B2-B5EE-F873E4F35542
P2860
Confronting the barriers to develop novel vaccines against brucellosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Confronting the barriers to develop novel vaccines against brucellosis.
@en
Confronting the barriers to develop novel vaccines against brucellosis.
@nl
type
label
Confronting the barriers to develop novel vaccines against brucellosis.
@en
Confronting the barriers to develop novel vaccines against brucellosis.
@nl
prefLabel
Confronting the barriers to develop novel vaccines against brucellosis.
@en
Confronting the barriers to develop novel vaccines against brucellosis.
@nl
P2860
P356
P1476
Confronting the barriers to develop novel vaccines against brucellosis.
@en
P2093
Guillermo Hernán Giambartolomei
Sérgio Costa Oliveira
P2860
P304
P356
10.1586/ERV.11.110
P577
2011-09-01T00:00:00Z